E.U. gives thumbs up for belantamab in R/R multiple myeloma
The first-in-class drug belantamab mafodotin (Blenrep, GlaxoSmithKline) has been recommended for conditional marketing approval in the EU.
Related Articles
Getting Patients With Opioid Use Disorder Started on Buprenorphine in Primary Care
Any DEA-registered PCP can prescribe buprenorphine and should screen for opioid use disorder, presenter says.
Federal Trade Commission Bans Noncompete Agreements, Urges More Protections for Healthcare Workers
But dissenting commissioners dispute the FTC’s authority to broadly ban noncompetes.
Could Modifying Gut Microbiota Enhance Response to Methotrexate in RA?
Investigators have found evidence suggesting that bad bugs in the belly may contribute to inflammation in the joints, and that modulating gut microbes could improve…
Physicians Own Less Than Half of US Practices; Federal Agencies Want Outside Input
A new report on trends in medical practice ownership came amid increased federal scrutiny of consolidation and the role of private equity.
Too Little Sleep Raises Health Risks for Teens With T1D
“Sleep may be an important and novel target for improving health in individuals with T1D, particularly when initiated in adolescence or early in diabetes.”
4 Years In, a Sobering Look at Long COVID Progress
Long COVID is still a disease diagnosed by figuring out what a patient does not have. Symptom management is the only treatment now.
Impact of Ketogenic and Low-Glycemic Diets on Inflammatory Skin Conditions
Diet plays an emerging role in dermatologic therapy. The ketogenic and low-glycemic diets have potential anti-inflammatory and metabolic effects, making them attractive for treating inflammatory…
Meta-analysis Identifies Atopic Dermatitis as Potential Risk Factor for Headache Disorder or Migraine
Key clinical point: Atopic dermatitis (AD) is significantly associated with a higher ri
IV Ketamine Promising for Severe Refractory Headache in Children
Overall, the treatment was “safe and well tolerated.”